NCT01163383 2026-04-13
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
Available
Clinical Trials
13 trialsNCT03581240 2026-02-20
An Intermediate Expanded Use Trial of DFMO
Milton S. Hershey Medical Center
Available
NCT07223606 2025-11-03
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
ProgenaBiome
No longer available
NCT05064306 2025-08-01
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Memorial Sloan Kettering Cancer Center
No longer available
NCT06872489 2025-07-23
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
Available
NCT01370330 2025-07-22
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
Available
NCT03649438 2024-12-11
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
University of Texas Southwestern Medical Center
No longer available
NCT03015844 2024-07-05
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Northwell Health
Available
NCT01838187 2023-08-18
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Children's Hospital Medical Center, Cincinnati
No longer available
NCT01590680 2023-02-28
Expanded Access Protocol Using 131I-MIBG
Jubilant DraxImage Inc.
Available
NCT02431715 2023-02-21
18F-FDOPA PET in Neuroendocrine Tumours
British Columbia Cancer Agency
No longer available
NCT02075177 2022-03-21
Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
South Plains Oncology Consortium
No longer available
NCT00730444 2009-11-09
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
GE Healthcare
Approved for marketing